Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Kura Oncology (KURA) EPS (Weighted Average and Diluted) (2023 - 2025)

Kura Oncology (KURA) has disclosed EPS (Weighted Average and Diluted) for 3 consecutive years, with -$0.92 as the latest value for Q4 2025.

  • On a quarterly basis, EPS (Weighted Average and Diluted) fell 319.93% to -$0.92 in Q4 2025 year-over-year; TTM through Dec 2025 was -$0.92, a 54.27% increase, with the full-year FY2025 number at -$3.18, down 57.43% from a year prior.
  • EPS (Weighted Average and Diluted) was -$0.92 for Q4 2025 at Kura Oncology, down from -$0.85 in the prior quarter.
  • In the past five years, EPS (Weighted Average and Diluted) ranged from a high of -$0.22 in Q4 2024 to a low of -$0.92 in Q4 2025.
  • A 3-year average of -$0.61 and a median of -$0.59 in 2024 define the central range for EPS (Weighted Average and Diluted).
  • Peak YoY movement for EPS (Weighted Average and Diluted): skyrocketed 60.0% in 2024, then plummeted 319.93% in 2025.
  • Kura Oncology's EPS (Weighted Average and Diluted) stood at -$0.55 in 2023, then surged by 60.0% to -$0.22 in 2024, then tumbled by 319.93% to -$0.92 in 2025.
  • Per Business Quant, the three most recent readings for KURA's EPS (Weighted Average and Diluted) are -$0.92 (Q4 2025), -$0.85 (Q3 2025), and -$0.76 (Q2 2025).